Chronic hepatitis B is a common chronic inflammatory disease of the liver in China that frequently results in sustained damage to the liver parenchyma, followed by liver fibrosis, and ultimately progresses to unfavorable outcomes such as cirrhosis, liver failure, and liver cancer. Liver fibrosis reversal can be achieved through early and effective intervention. Therefore, timely and accurate assessment of the degree of liver fibrosis is of great clinical significance for the treatment and prognosis assessment of patients with chronic hepatitis B. MRI plays a crucial role in the early assessment and monitoring of the therapeutic efficacy of liver fibrosis in chronic hepatitis B. Currently, there is a lack of uniform consensus on MRI scanning protocols and related diagnostic thresholds for liver fibrosis in chronic hepatitis B, which is not conducive to practical clinical evaluation and application. This expert consensus is based on a full review of relevant domestic and international literature and the formulation of methodologies based on evidence-based medical guidelines and standards to develop recommendations for MRI scanning techniques and the diagnosis of liver fibrosis in chronic hepatitis B, with a view to providing a clear basis for the clinical diagnosis.
慢性乙型肝炎是中国常见的肝脏慢性炎症性疾病，常导致肝实质持续损伤，继而发生肝纤维化，最终可导致肝硬化、肝功能衰竭、肝癌等不良结局。肝纤维化早期有效干预可实现肝纤维化的逆转。因此，及时准确评估肝纤维化程度对慢性乙型肝炎患者的治疗及预后评估具有重要的临床意义。MRI在慢性乙型肝炎肝纤维化的早期评估及疗效监测中发挥着至关重要的作用。目前慢性乙型肝炎肝纤维化MRI扫描方案及相关诊断阈值缺乏统一共识，不利于临床的实际评估与运用。该专家共识在充分复习国内外相关文献的基础上，基于循证医学指南及标准制订方法学，形成慢性乙型肝炎肝纤维化MRI扫描技术及诊断推荐意见，以期为临床肝纤维化诊断提供明确的依据。.

The European Association for the Study of the Liver has recently published updated guidelines on the use of non-invasive tests to identify and stratify chronic liver disease. Here, we provide a summary of the key recommendations from the guideline.

In 2006, the Hepatology Committee of Chinese Association of Integrative Medicine issued the \"Guidelines for the Prevention and Treatment of Liver Fibrosis with Integrated Traditional Chinese and Western Medicine.\" In recent years, the fields of Chinese medicine, Western medicine, and integrative medicine have made rapid advances in basic and clinical research into chronic liver disease, and accumulated new evidence for the prevention and treatment of hepatic fibrosis. Therefore, in order to meet clinical needs, liver disease experts of integrated traditional Chinese and Western medicine were united to revise the previous guidelines in order to help physicians make correct and reasonable decisions in the diagnosis and treatment of hepatic fibrosis.

Mannose phosphate isomerase-congenital disorder of glycosylation (MPI-CDG) deficiency is a rare subtype of congenital disorders of protein N-glycosylation. It is characterised by deficiency of MPI caused by pathogenic variants in MPI gene. The manifestation of MPI-CDG is different from other CDGs as the patients suffer dominantly from gastrointestinal and hepatic involvement whereas they usually do not present intellectual disability or neurological impairment. It is also one of the few treatable subtypes of CDGs with proven effect of oral mannose. This article covers a complex review of the literature and recommendations for the management of MPI-CDG with an emphasis on the clinical aspect of the disease. A team of international experts elaborated summaries and recommendations for diagnostics, differential diagnosis, management, and treatment of each system/organ involvement based on evidence-based data and experts\' opinions. Those guidelines also reveal more questions about MPI-CDG which need to be further studied.

Hepatic fibrosis is a reparative response of diffuse over-deposition and abnormal distribution of extracellular matrix (collagen, glycoprotein and proteoglycans) after exposure to various kinds of liver injuries, and is a key step in the developmental process of various chronic liver diseases leading to cirrhosis. Recently, many advances in our understanding of hepatic fibrosis have been obtained through basic and clinical research. Therefore, this consensus summarizes and offers 15 evidence-based recommendations on the diagnosis and evaluation of hepatic fibrosis, its treatment, drug development and applications.

Hepatic fibrosis is a reparative response of diffuse over deposition and abnormal distribution of extracellular matrix (collagen, glycoprotein and proteoglycans) after exposure to various kinds of liver injuries, and is a key step in the developmental process of various chronic liver diseases to cirrhosis. Recently, many advances in our understanding of hepatic fibrosis have been recognized through the basic and clinical research. Therefore, we have organized the relevant domestic experts of this field to form consensus on the diagnosis and evaluation, treatment, and clinical development and application of therapy in order to better guide the diagnosis and treatment, and drug research and development.
肝纤维化是肝脏受到各种损伤后细胞外基质(即胶原、糖蛋白和蛋白多糖等)弥漫性过度沉积与异常分布的修复反应，是各种慢性肝病向肝硬化发展过程中的关键步骤。近年来对肝纤维化基础和临床研究及其认识方面有不少进展，我们为此组织了国内本领域相关专家，就肝纤维化诊断和评估、肝纤维化治疗及肝纤维化治疗药物临床开发应用形成共识，以便更好地指导肝纤维化诊断和治疗及药物研发。.

In 2006, the Hepatology Committee, Chinese Association of the Integration of Traditional and Western Medicine issued the \"Guidelines for the Prevention and Treatment of Liver Fibrosis with Integrated Traditional Chinese and Western Medicine\" . In recent years, in the field of modern medicine and integrated Chinese and Western medicine, the basic and clinical research into chronic liver disease has made rapid progress, and accumulated new evidence for the prevention and treatment of liver fibrosis. Therefore, in order to meet the clinical needs, experts of integrated traditional Chinese and Western medicine of liver diseases were united to revise the previous guidelines in order to help physicians make correct and reasonable decisions in the diagnosis and treatment of liver fibrosis.
中国中西医结合学会肝病专业委员会于2006年发布了\"肝纤维化中西医结合诊疗指南\"。近年来，在现代医学和中西医结合领域，慢性肝病的基础和临床的研究均取得快速进展，为肝纤维化防治积累了新的证据。因此，为满足临床需要，我们组织中西医结合肝病领域的专家，对指南进行了修订，旨在帮助医师在肝纤维化的诊断和治疗过程中作出正确合理的决策。.